15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026.
The sale accounted for 22.9% of Andrew Callos’ direct holdings, reducing his position from 65,440 to 50,440 shares.
This was a derivative-related event involving the immediate exercise and sale of options; no indirect entities or trusts participated.
Transaction size exceeded Callos’ historical median sell trade, reflecting reduced remaining capacity after significant prior dispositions.
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK), exercised 15,000 options for common stock and immediately sold the resulting shares in an open-market transaction totaling approximately $928,950, according to the SEC Form 4 filing.
| Metric | Value |
|---|---|
| Shares sold (direct) | 15,000 |
| Transaction value | ~$928,950 |
| Post-transaction shares (direct) | 50,440 |
| Post-transaction value (direct ownership) | ~$3.0 million |
Transaction value based on SEC Form 4 weighted average purchase price ($61.93); post-transaction value based on Feb. 5, 2026 market close ($60.24).
| Metric | Value |
|---|---|
| Price (as of market close 2/5/26) | $51.00 |
| Market capitalization | $7.62 billion |
| Revenue (TTM) | $87.21 million |
| Net income (TTM) | ($785.0 million) |
Cytokinetics is a late-stage biopharmaceutical company specializing in muscle biology, with a strategic focus on novel therapeutics for debilitating cardiac and neuromuscular conditions. The company leverages advanced small molecule research and clinical development capabilities to build a pipeline of differentiated assets. Its competitive position is supported by a robust clinical portfolio and strategic alliances within the healthcare industry.
A Cytokinetics executive converted nearly $929,000 worth of stock options in early February, just weeks after the company’s first commercial product hit pharmacy shelves. The transaction was an exercise-and-sell of vested options, which is the type of routine equity compensation event common at biotech companies.
Still, the timing is notable. CYTK had surged more than 92% in the six months leading up to the FDA’s December 2025 approval of myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy, meaning Callos’ options had accumulated significant value by the time he exercised them at roughly $62 per share.
Myqorzo became available by U.S. prescription in January 2026, making this the company’s first real test as a commercial-stage business. Cytokinetics posted a net loss of nearly $785 million in 2025 as it invested heavily in launch readiness.
For investors comfortable with the volatility that comes with the biotech industry, CYTK represents a company at a genuine inflection point. The stock may appeal to those with a higher risk tolerance who are drawn to specialty cardiovascular plays with blockbuster potential. Key things to watch: how quickly cardiologists adopt myqorzo, whether label expansion trials deliver, and how efficiently the company manages its cash burn as it scales.
Before you buy stock in Cytokinetics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cytokinetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $534,008!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,090,073!*
Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 9, 2026.
Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
